2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

Gregory Y H Lip, Jean-Phillippe Collet, Michael Haude, Robert Byrne, Eugene H Chung, Laurent Fauchier, Sigrun Halvorsen, Dennis Lau, Nestor Lopez-Cabanillas, Maddalena Lettino, Francisco Marin, Israel Obel, Andrea Rubboli, Robert F Storey, Marco Valgimigli, Kurt Huber, ESC Scientific Document Group

Research output: Contribution to journalReview articleResearchpeer-review

32 Citations (Scopus)

Abstract

In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.

Original languageEnglish
JournalEuropace
Volume21
Issue number2
Pages (from-to)192-193
Number of pages2
ISSN1099-5129
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

Southern Africa
Latin America
Acute Coronary Syndrome
Atrial Fibrillation
Cardiac Arrhythmias
Thrombosis
Joints
Therapeutics
Publications
Randomized Controlled Trials
Guidelines
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • Acute coronary syndrome
  • Anticoagulation
  • Antiplatelet agents
  • Antithrombotic therapy
  • Atrial fibrillation
  • Bleeding
  • Consensus document
  • Coronary artery disease
  • European Heart Rhythm Association
  • Left atrial appendage occlusion
  • Low molecular weight heparin
  • Myocardial infarction
  • Non-Vitamin K antagonist oral anticoagulants
  • Parenteral anticoagulants
  • Percutaneous coronary intervention
  • Position paper
  • Stent
  • Stroke
  • Thromboembolism
  • Thrombosis
  • Vitamin K antagonists

Cite this

@article{3e5f86cf228346fd90e2fbc74ae54558,
title = "2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)",
abstract = "In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.",
keywords = "Acute coronary syndrome, Anticoagulation, Antiplatelet agents, Antithrombotic therapy, Atrial fibrillation, Bleeding, Consensus document, Coronary artery disease, European Heart Rhythm Association, Left atrial appendage occlusion, Low molecular weight heparin, Myocardial infarction, Non-Vitamin K antagonist oral anticoagulants, Parenteral anticoagulants, Percutaneous coronary intervention, Position paper, Stent, Stroke, Thromboembolism, Thrombosis, Vitamin K antagonists",
author = "Lip, {Gregory Y H} and Jean-Phillippe Collet and Michael Haude and Robert Byrne and Chung, {Eugene H} and Laurent Fauchier and Sigrun Halvorsen and Dennis Lau and Nestor Lopez-Cabanillas and Maddalena Lettino and Francisco Marin and Israel Obel and Andrea Rubboli and Storey, {Robert F} and Marco Valgimigli and Kurt Huber and {ESC Scientific Document Group}",
year = "2019",
month = "2",
day = "1",
doi = "10.1093/europace/euy174",
language = "English",
volume = "21",
pages = "192--193",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions

T2 - a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

AU - Lip, Gregory Y H

AU - Collet, Jean-Phillippe

AU - Haude, Michael

AU - Byrne, Robert

AU - Chung, Eugene H

AU - Fauchier, Laurent

AU - Halvorsen, Sigrun

AU - Lau, Dennis

AU - Lopez-Cabanillas, Nestor

AU - Lettino, Maddalena

AU - Marin, Francisco

AU - Obel, Israel

AU - Rubboli, Andrea

AU - Storey, Robert F

AU - Valgimigli, Marco

AU - Huber, Kurt

AU - ESC Scientific Document Group

PY - 2019/2/1

Y1 - 2019/2/1

N2 - In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.

AB - In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.

KW - Acute coronary syndrome

KW - Anticoagulation

KW - Antiplatelet agents

KW - Antithrombotic therapy

KW - Atrial fibrillation

KW - Bleeding

KW - Consensus document

KW - Coronary artery disease

KW - European Heart Rhythm Association

KW - Left atrial appendage occlusion

KW - Low molecular weight heparin

KW - Myocardial infarction

KW - Non-Vitamin K antagonist oral anticoagulants

KW - Parenteral anticoagulants

KW - Percutaneous coronary intervention

KW - Position paper

KW - Stent

KW - Stroke

KW - Thromboembolism

KW - Thrombosis

KW - Vitamin K antagonists

UR - http://www.scopus.com/inward/record.url?scp=85054470587&partnerID=8YFLogxK

U2 - 10.1093/europace/euy174

DO - 10.1093/europace/euy174

M3 - Review article

VL - 21

SP - 192

EP - 193

JO - Europace

JF - Europace

SN - 1099-5129

IS - 2

ER -